Cronos Group Stock Performance
| CRON Stock | USD 2.07 0.02 0.96% |
On a scale of 0 to 100, Cronos holds a performance score of 7. The firm shows a Beta (market volatility) of 0.11, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cronos' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cronos is expected to be smaller as well. Please check Cronos' semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Cronos' price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cronos Group are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Cronos displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 669.3 M | |
| Total Cashflows From Investing Activities | 175.1 M |
Cronos Relative Risk vs. Return Landscape
If you would invest 183.00 in Cronos Group on April 27, 2025 and sell it today you would earn a total of 22.00 from holding Cronos Group or generate 12.02% return on investment over 90 days. Cronos Group is currently generating 0.2008% in daily expected returns and assumes 2.0522% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than Cronos, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cronos Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cronos' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cronos Group, and traders can use it to determine the average amount a Cronos' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0978
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CRON | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.05 actual daily | 18 82% of assets are more volatile |
Expected Return
| 0.2 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Cronos is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cronos by adding it to a well-diversified portfolio.
Cronos Fundamentals Growth
Cronos Stock prices reflect investors' perceptions of the future prospects and financial health of Cronos, and Cronos fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cronos Stock performance.
| Return On Equity | 0.0459 | ||||
| Return On Asset | -0.0242 | ||||
| Profit Margin | 0.40 % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | (34.32 M) | ||||
| Shares Outstanding | 385.42 M | ||||
| Price To Earning | 36.41 X | ||||
| Price To Book | 0.76 X | ||||
| Price To Sales | 6.40 X | ||||
| Revenue | 117.61 M | ||||
| EBITDA | (50.21 M) | ||||
| Cash And Equivalents | 944.89 M | ||||
| Cash Per Share | 2.50 X | ||||
| Total Debt | 2.02 M | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | 2.77 X | ||||
| Cash Flow From Operations | 18.84 M | ||||
| Earnings Per Share | 0.14 X | ||||
| Total Asset | 1.17 B | ||||
| Retained Earnings | 457.71 M | ||||
| Current Asset | 15.37 M | ||||
| Current Liabilities | 10.59 M | ||||
About Cronos Performance
By examining Cronos' fundamental ratios, stakeholders can obtain critical insights into Cronos' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Cronos is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada. Cronos operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 626 people.Things to note about Cronos Group performance evaluation
Checking the ongoing alerts about Cronos for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cronos Group help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cronos Group has a strong financial position based on the latest SEC filings | |
| About 47.0% of the company shares are held by company insiders |
- Analyzing Cronos' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cronos' stock is overvalued or undervalued compared to its peers.
- Examining Cronos' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cronos' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cronos' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cronos' stock. These opinions can provide insight into Cronos' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cronos Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cronos. If investors know Cronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cronos listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cronos Group is measured differently than its book value, which is the value of Cronos that is recorded on the company's balance sheet. Investors also form their own opinion of Cronos' value that differs from its market value or its book value, called intrinsic value, which is Cronos' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cronos' market value can be influenced by many factors that don't directly affect Cronos' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cronos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cronos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cronos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.